International consensus on axillary staging after neoadjuvant chemotherapy in node-positive breast cancer
- 15 April 2026
- journal article
- consensus statement
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (11) , 111791
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant ChemotherapyJAMA Oncology, 2024
- Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast CancerJAMA Surgery, 2022
- Diagnostic accuracy of de‐escalated surgical procedure in axilla for node‐positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta‐analysisCancer Medicine, 2022
- Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocolBreast Cancer Research and Treatment, 2022
- A Consensus-Based Checklist for Reporting of Survey Studies (CROSS)Journal of General Internal Medicine, 2021
- Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive DiseaseJAMA Surgery, 2021
- The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT)The Breast, 2017
- Magnetic Resonance Imaging for Axillary Breast Cancer Metastasis in the Neoadjuvant Setting: A Prospective StudyClinical Breast Cancer, 2017
- Surgeon Specialization and Use of Sentinel Lymph Node Biopsy for Breast CancerJAMA Surgery, 2014
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013